Positive interim Phase 2 data for TFF VORI and TFF TAC; company to accelerate to registration-enabling studies

TFF Pharmaceuticals, Inc.

All five TFF VORI patients achieved clinical and mycologic responses; no all-cause mortality or discontinuations due to AEs.
All four TFF TAC patients transitioned from oral tacrolimus with reduced blood levels; no acute rejection; kidney function maintained.
Company plans to accelerate initiation of registration-enabling studies for both TFF VORI and TFF TAC.
1-for-25 reverse stock split effective December 19, reducing shares from ~59M to ~2.4M.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TFF Pharmaceuticals, Inc.: Filed Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2023-12-19).

Change: charter amendment
Effective: 2023-12-19

Exact text from the filing

On December 18, 2023, TFF Pharmaceuticals, Inc. (the “Company”) filed with the Delaware Secretary of State a Certificate of Amendment (“Amendment”) to its Second Amended and Restated Certificate of Incorporation to effect a one for twenty-five (25) reverse stock split (“Reverse Split”) of its issued and outstanding shares of common stock. The effective time of the Reverse Split is 12:01 AM ET on December 19, 2023.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001213900-23-096633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.